Please login to the form below

Not currently logged in
Email:
Password:

TT701

This page shows the latest TT701 news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

The big pharma company pockets just $1m upfront from the deal, although Transition could pay up to $100m in milestones if the small-molecule drug - called TT701 - eventually reaches the market. ... TT701 is a selective androgen receptor modulator (SARM)

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Transition Therapeutics with the out-licence of the phase II ready selective androgen receptor modulator TT701 to Transition. ... 105.5. Eli Lilly/ Transition Therapeutics. Licence agreement. For TT701 a selective androgen receptor modulator in P2 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics